Physician profile
Jason Ludwig
NPI 1144258534
$7,478.53
in general payments reported to CMS, 2019-2025
70 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $759 · 2021: $1,013 · 2022: $1,130 · 2023: $1,008 · 2024: $1,137 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,588.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $828.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $455.69 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $453.00 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $345.92 | 2019-2025 | |
| Abbvie INC. | $309.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $274.80 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $253.23 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Glaxosmithkline, LLC. | $238.33 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $238.13 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $214.83 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $206.59 | 2019-2024 | Xarelto, Spravato |
| Corium, LLC | $183.68 | 2022-2025 | Azstarys |
| Allergan, INC. | $181.12 | 2019-2020 | |
| Dexcom, INC. | $172.43 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $152.06 | 2021-2024 | Eliquis |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ludwig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.